Active substanceInosineInosine
Similar drugsTo uncover
  • Inosie-F®
    solution in / in 
    Europharm (UK) Co., Ltd.     United Kingdom
  • Inosine
    solution in / in 
    Ama Pharm, OOO     China
  • Inozin-Eskom
    solution in / in 
    ESKOM NPK, OAO     Russia
  • Riboxin
    solution in / in 
    ATOLL, LLC     Russia
  • Riboxin
    solution in / in 
  • Riboxin
    solution in / in 
  • Riboxin
    pills inwards 
    VALENTA PHARM, PAO     Russia
  • Riboxin
    solution in / in 
  • Riboxin
    pills inwards 
    IRBITSK HFZ, OJSC     Russia
  • Riboxin
    pills inwards 
  • Riboxin
    solution in / in 
  • Riboxin
    solution in / in 
  • Riboxin
    pills inwards 
  • Riboxin
    pills inwards 
    MAKSFARM, OJSC     Russia
  • Riboxin
    solution in / in 
  • Riboxin
    pills inwards 
    BINNOFARM, CJSC     Russia
  • Riboxin
    pills inwards 
  • Riboxin
    pills inwards 
    OZONE, LLC     Russia
  • Riboxin
    pills inwards 
    BIOSINTEZ, PAO     Russia
  • Riboxin
    pills inwards 
  • Riboxin
    pills inwards 
    DALHIMFARM, OJSC     Russia
  • Riboxin
    solution in / in 
    BIOSINTEZ, PAO     Russia
  • Riboxin
    pills inwards 
    NORTH STAR, CJSC     Russia
  • Riboxin
    capsules inwards 
    MINSKINTERKAPS, UP     Republic of Belarus
  • Riboxin
    solution in / in 
    VEROPHARM SA     Russia
  • Riboxin
    pills inwards 
    Mapichem AG     Switzerland
  • Riboxin
    solution in / in 
    Mapichem AG     Switzerland
  • Riboxin
    solution in / in 
    DALHIMFARM, OJSC     Russia
  • Riboxin
    solution in / in 
    ELLARA, LTD.     Russia
  • Riboxin
    solution in / in 
    GROTEKS, LLC     Russia
  • Riboxin
    solution in / in 
    VELFARM, LLC     Republic of San Marino
  • Riboxin of Avexime
    pills inwards 
  • Riboxin Beefus
    solution in / in 
    UPDATE OF PFC, CJSC     Russia
  • Riboxin-Vial
    solution in / in 
    VIAL, LLC     Russia
  • Riboxin-LexT
    pills inwards 
  • Riboxin-Ferein
    pills inwards 
    BRYNTSALOV-A, CJSC     Russia
  • ASFARMA, LLC     Russia
  • Dosage form: & nbspfilm-coated tablets
    Composition:

    Each tablet contains:

    active substance: inosine (riboxin) (in terms of 100% substance) 200 mg;

    Excipients: sucrose (sugar cane), potato starch, magnesium stearate;

    shell: (E5), hydroxypropylmethylcellulose (E3), glyceryl monoacetate (3-glyceride acetate), polyvinyl alcohol, macrogol (polyethylene glycol), titanium dioxide (titanium pigment), kaempferol (indigo yellow), talc.

    Description:

    Round, yellow, biconvex tablets, covered with a film membrane.

    Pharmacotherapeutic group:metabolic
    ATX: & nbsp

    C.01.E.B   Other drugs for the treatment of heart disease

    Pharmacodynamics:

    Metabolic agent, the precursor of ATP; has antihypoxic, metabolic and antiarrhythmic effects. Increases the energy balance of the myocardium, improves coronary circulation, prevents the consequences of intraoperative kidney ischemia. It takes a direct part in the exchange of glucose and promotes the activation of metabolism in conditions of hypoxia and in the absence of ATP. Activates the metabolism of pyruvic acid to ensure a normal process of tissue respiration, and also promotes the activation of xanthine dehydrogenase. Stimulates the synthesis of nucleotides, enhances the activity of certain enzymes of the Krebs cycle.Penetrating into cells, increases the energy level, has a positive effect on the metabolic processes in the myocardium - increases the strength of the contractions of the heart and promotes more complete relaxation of the myocardium in diastole, resulting in an increased shock volume. Reduces platelet aggregation, activates the regeneration of tissues (especially the myocardium and the mucous membrane of the gastrointestinal tract (GIT).

    Pharmacokinetics:

    It is well absorbed in the digestive tract, metabolized in the liver with the formation of glucuronic acid and its subsequent oxidation. In a small amount, it is excreted by the kidneys.

    Indications:

    Assign adults in the complex therapy of coronary heart disease, myocardial dystrophy, after myocardial infarction, heart rhythm disorders due to the use of cardiac glycosides.

    Assign with hepatitis, cirrhosis, fatty liver, caused by alcohol or drugs and urocoppororphy.

    Contraindications:Hypersensitivity, gout, hyperuricemia.
    Carefully:Renal failure.
    Dosing and Administration:

    Assign inside before eating.

    The daily intake for oral administration is 0.6-2.4 g. In the first days of treatment, the daily dose is 0.6-0.8 g (0.2 g 3-4 times a day). In case of good tolerance, the dose is increased (2-3 days) by 1.2 g (0.4 g 3 times a day), if necessary - up to 2.4 g per day.

    The duration of the course is from 4 weeks to 1.5-3 months.

    With urocoppororphy, the daily dose is 0.8 g (0.2 g 4 times a day). The drug is taken daily for 1-3 months.

    Side effects:

    Allergic reactions are possible in the form of hives, itchy skin, skin hyperemia (drug withdrawal is required).

    Rarely with the treatment of the drug raises the concentration of uric acid in the blood and exacerbation of gout (with prolonged use).

    Form release / dosage:

    Tablets, film-coated, 200 mg.

    Packaging:

    10 tablets in a contour mesh box made of polyvinylchloride film and aluminum foil or packaging material.

    50 tablets are placed in polymer bottles. The neck of the polymer bottle is covered with a moisture-proof aluminum foil and a screw cap.

    1 bottle or 5 contour mesh packages together with instructions for use are placed in a cardboard box.

    Storage conditions:

    Store in a dry, dark place at a temperature of no higher than 25 ° C.

    Keep out of the reach of children.

    Shelf life:

    3 years.

    Do not use after expiry date.

    Terms of leave from pharmacies:On prescription
    Registration number:LSR-001523/08
    Date of registration:14.03.2008
    The owner of the registration certificate: Mapichem AG Mapichem AG Switzerland
    Manufacturer: & nbsp
    Representation: & nbspMapichem AGMapichem AG
    Information update date: & nbsp23.10.2015
    Illustrated instructions
      Instructions
      Up